Here we describe, to our knowledge, the first report of therapeutic dosing of a selective, dual small molecule inhibitor of PKCα and PKCβ in a rodent model of obesity-driven T2D characterized by progressive renal impairment. This evidence concerns the gene PRKCA and type 2 diabetes mellitus.